Final Program - American Society of Gene & Cell Therapy

More documents

Recommendations

Info

Program Schedule, Thursday, May 16, 2013 Plenary Session 300 8:00 am - 9:00 am ROOM: BALLROOM E-J Outstanding Achievement Award Lecture and Presentation of the Distinguished Service Award and Special Recognition Award CHAIR Katherine P. Ponder, MD DISTINGUISHED SERVICE AWARD RECIPIENTS SPECIAL RECOGNITION AWARD RECIPIENT Sonia I. Skarlatos, PhD Catherine McKeon, PhD John J. Rossi, PhD SPEAKER Thursday, May 16, 2013 Mark A. Kay, MD, PhD Deciphering Vector and Non-coding RNA Biology: A New Frontier in Nucleic Acid based Therapies In the last decade, we have witnessed great improvements in vector biology and utilized these for novel biomedical discoveries and therapeutic applications. In addition, it is now established that over 90% of the genome is transcribed, yet the role for most of the non-coding RNAs remains unclear. I will discuss our studies aimed at both uncovering the generation and function of non-coding RNAs, as well as the mechanisms important for the development of new vector-based gene transfer approaches to manipulate gene expression. Together, these approaches have provided continued and powerful insight into gene therapy mechanisms used to treat an array of diseases. Exhibit Hall Coffee Social 9:00 am - 9:45 am ROOM: EXHIBIT HALL C/D Final Program SALT LAKE CITY, UTAH May 15–18, 2013 57
Program Schedule, Friday, May 17, 2013 Scientific Symposium 310 9:45 am - 11:45 am ROOM: BALLROOM D Cancer Gene and Cell Therapy: Results from Clinical Trials CO-CHAIRS: Evanthia Galanis, MD, DSc and Juan F. Vera, MD SPEAKERS Svend O. Freytag, PhD Randomized, Controlled, Phase 2 Trial of Oncolytic Adenovirus-mediated Suicide Gene Therapy Plus IMRT Versus IMRT Alone in neWly-diagnosed, Intermediate-risk Prostate Cancer We have developed a multi-modal, gene therapy-based approach for the treatment of cancer involving an oncolytic adenovirus, suicide gene therapy and radiation therapy. We have evaluated the safety and eficacy of our approach in six clinical trials, including a randomized, controlled phase 2 trial in prostate cancer. The results of these clinical studies will be presented and the lessons learned discussed. Evanthia Galanis, MD, DSc Oncolytic Measles Virus Strains in Cancer Treatment Trials: An Update Measles virus is a negative strand RNA virus (paramyxovirus) with oncolytic properties. The signiicant preclinical activity of MV- Edmonston vaccine strains against multiple different animal tumor models, their potent bystander effect, their selectivity against tumor cells, and their ability to retain their oncolytic properties when engineered and retargeted, makes them a promising oncolytic platform. Two trackable engineered measles virus strain derivatives are currently in clinical testing; a derivative expressing the human carcinoembryonic antigen (MV-CEA) and a strain expressing the human sodium iodine symporter (MV-NIS). Phase I/II trials are ongoing or have been completed in ovarian cancer, glioblastoma multiforme, multiple myeloma, mesothelioma and head and neck cancer and a phase I/II trial of mesenchymal stem cell delivery will be activated later this year. Clinical data to date, challenges in clinical applications of oncolytic measles virus strains and preclinical data supporting future translational directions will be discussed. Friday, May 17, 2013 Renier J. Brentjens, MD, PhD CAR Modiied T-cells, From the Bench to the Bedside T cells may be genetically modiied to express artiicial T cell receptors, termed chimeric antigen receptors or CARs targeted to tumor associated antigens. Previous work in preclinical models has demonstrated the potential of this approach in targeting T cells to systemic tumor and in turn eradicating tumor. More recently, we and others have successfully moved this technology to the clinical setting demonstrating early very promising responses with CD19 targeted CAR modiied T cells in patients with relapsed B cell malignancies including acute lymphoblastic and chronic lymphocytic leukemias as well as indolent B cell non-Hodgkins lymphomas. However, limitations to this adoptive T cell approach need to be addressed before this approach may be successfully optimized to B cell malignancies and further expanded to other cancers targeting other tumor associated antigens. One such an approach is the design of “armored CAR” T cells additionally modiied to express cytokines or co-stimulatory ligands to enhance in vivo cytotoxicity as well as persistence of CAR modiied T cells following infusion. Stephen Gottschalk, MD Cell Therapies for Solid Tumors: Successes and Challenges The outcome for patients with advanced solid tumors has not signiicantly improved over the last 2 decades. Thus, new targeted therapies are needed to improve current outcomes, and T-cell immunotherapy has the potential to fulill this need. In my talk I will review i) the use of Epstein-Barr virus (EBV)-speciic T cells to treat patients with advanced stage EBV+ nasopharyngeal carcinoma, ii) our recent studies to target solid tumors and their supporting stroma with chimeric antigen receptor (CAR) T cells, and iii) novel approaches to render T cells speciic for solid tumor antigens. 58 Final Program SALT LAKE CITY, UTAH May 15–18, 2013
Page 2 and 3:
ASGCT Officers and Board of Directo
Page 4 and 5:
Annual Meeting Exhibitors - as of A
Page 6 and 7:
Annual Meeting Supporters Patron Le
Page 8 and 9: Committee Rosters Advisory Council
Page 10 and 11: Committee Rosters Host Committee Ch
Page 12 and 13: Committee Rosters Program Committee
Page 14 and 15: Abstract Reviewers Cancer - Immunot
Page 16 and 17: Outstanding New Investigator Awards
Page 18 and 19: Faculty List Thomas W. Chalberg, Jr
Page 20 and 21: Faculty List Ann M. Leen, PhD Baylo
Page 22 and 23: Faculty List Evan Y. Snyder, MD PhD
Page 24 and 25: General Meeting Information Continu
Page 26 and 27: General Meeting Information Speaker
Page 28 and 29: Salt Palace Convention Center Floor
Page 30 and 31: Salt Palace Convention Center Floor
Page 32 and 33: Program Schedule, Wednesday, May 15
Page 48 and 49: Program Schedule, Thursday, May 16,
Page 60 and 61: Program Schedule, Friday, May 17, 2
Page 70 and 71: Program Schedule, Saturday, May 18,
Page 80 and 81: Exhibitor Descriptions Aldevron 323
Page 82 and 83: Exhibitor Descriptions HypOxygen 51
Page 84 and 85: Exhibitor Descriptions Panasonic He
Page 86 and 87: Exhibitor Descriptions University o
Page 88 and 89: Abstract Directory, Wednesday, May
Page 94 and 95: Abstract Directory, Thursday, May 1
Page 108 and 109:
Abstract Directory, Thursday, May 1
Page 110 and 111:
Abstract Directory, Friday, May 17,
Page 112 and 113:
Page 114 and 115:
Page 116 and 117:
Page 118 and 119:
Page 120 and 121:
Page 122 and 123:
Page 124 and 125:
Page 126 and 127:
Abstract Directory, Saturday, May 1
Page 128 and 129:
Page 130 and 131:
Page 132 and 133:
Page 134 and 135:
Page 136 and 137:
Page 138 and 139:
Page 140 and 141:
Abstract Author Index Aartsma-Rus,
Page 142 and 143:
Abstract Author Index Bartel, Ronnd
Page 144 and 145:
Abstract Author Index Bridges, Char
Page 146 and 147:
Abstract Author Index Chicoine, Lou
Page 148 and 149:
Abstract Author Index Daukandt, Mar
Page 150 and 151:
Abstract Author Index Eleftheriadou
Page 152 and 153:
Abstract Author Index Furth, Mark E
Page 154 and 155:
Abstract Author Index Grosso, Chant
Page 156 and 157:
Abstract Author Index Hickey, Ray D
Page 158 and 159:
Abstract Author Index Jacobs, Edwin
Page 160 and 161:
Abstract Author Index Kildebeck, Er
Page 162 and 163:
Abstract Author Index Lankester, Ar
Page 164 and 165:
Abstract Author Index Ling, Changqu
Page 166 and 167:
Abstract Author Index Martin, Dougl
Page 168 and 169:
Abstract Author Index Morishita, Na
Page 170 and 171:
Abstract Author Index Okamoto, Sach
Page 172 and 173:
Abstract Author Index Potter, Phil
Page 174 and 175:
Abstract Author Index Ruggiero, Eli
Page 176 and 177:
Abstract Author Index Shirakawa, To
Page 178 and 179:
Abstract Author Index Swanson, Magd
Page 180 and 181:
Abstract Author Index Ugai, Hideyo.
Page 182 and 183:
Abstract Author Index Watts, Korash
Page 184 and 185:
Abstract Author Index Yanovich, Sau
show all

Final Program - American Society of Gene & Cell Therapy

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?